The ICIs currently approved for cancer treatment targeting programmed death-1 (PD-1) and its ligand programmed death ligand (PDL)-1 have proven therapeutic efficacy for treatment of advanced melanoma, renal cell cancer, colorectal cancer, and non-small-cell lung cancer (NSCLC) [2,3,4]. This evidence concerns the gene CD274 and cancer.